SILICON VALLEY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Predicine, a global molecular insights company, announces the launch of PredicineCOMPLETE™, the most comprehensive next-generation liquid biopsy solution combining genome-wide, genomic and epigenomic insights to transform the To understand the mutational landscape and the immune signature of cancer and to contribute to the support of cancer research and clinical drug development.
New dates will be published on the 37thth Society for Immunotherapy Cancer (SITC) Annual Conference, November 8-12 in Boston, demonstrating the clinical utility of Predicine’s genome-wide liquid biopsy solution. The data relate to Predicine’s blood-based whole genome methylation (PredicineEPIC™), low-pass whole genome sequencing (PredicineCNB™) and enhanced whole genome sequencing (PredicineWES+™).
“Liquid biopsy has entered an era of genome-wide molecular profiling. There is a clear need to understand the full molecular profile of tumor cells, tumor microenvironment and post-therapy disease evolution,” said Shidong Jia, Founder and Global CEO of Predicine. “PredicineCOMPLETE™ closes the last mile in a comprehensive genomic mutation profile and epigenomic methylation insights to better understand disease biology, therapy response, minimal residual disease and drug resistance mechanisms, with the goal of further supporting clinical drug development in immuno-oncology and targeted therapy, among others applications.”
About predication
Predicine is a global molecular insights company dedicated to advancing precision medicine in oncology and infectious disease diagnostics. Predicine is developing proprietary cell-free DNA and cell-free RNA-based liquid biopsy technologies to enable minimally invasive molecular diagnosis for cancer screening, treatment selection, therapy response, minimal residual disease monitoring and disease progression. The Predicine portfolio includes blood-, urine- and tissue-based NGS assays…
[ad_2]
Source story
